Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 4/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 3/20 | 0.34 |
| ▸ | BRAF | P15056 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365570 | 1.00 | CA2 (0.37) | CA2CA9IDH2IRAK1RORC | |
| SCHEMBL19670369 | 0.90 | NAMPT (0.41) | CA2CA9IDH2IRAK1RORC | |
| SCHEMBL19669054 | 0.90 | NAMPT (0.41) | CA2CA9IDH2IRAK1RORC | |
| SCHEMBL17618887 | 0.90 | CA2 (0.38) | CA2CA9IDH2KDM4EUSP2 | |
| SCHEMBL19365807 | 0.90 | CA2 (0.38) | CA2CA9IDH2KDM4EUSP2 | |
| SCHEMBL16250024 | 0.90 | NAMPT (0.41) | CA2CA9IDH2IRAK1RORC | |
| SCHEMBL19670349 | 0.90 | CA2 (0.38) | CA2CA9IDH2KDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL17770586 | 0.87 | NAMPT (0.39) | CA2CA9IRAK1RORCSCN9A | |
| SCHEMBL17618888 | 0.85 | NAMPT (0.42) | CA2CA9RORCNPY2RSCN9A | |
| SCHEMBL20632518 | 0.85 | IDH2 (0.35) | CA2CA9IDH2IRAK1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA2 4636/4885CA9 4430/4885IDH2 42/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA2 4253/4885CA9 4248/4885IDH2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.